AU
UK
CA
NZ
IND
US
Last update at 2026-06-04T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Recce Pharmaceuticals targets Middle East expansion with 10-year R327G licensing deal
Wed 27 May 26, 12:21 AM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -13.07742M | -10.98628M | -13.51337M | -4.31674M | -2.78920M |
| Minority interest | - | - | - | - | - |
| Net income | -13.07742M | -10.98628M | -13.51337M | -4.31674M | -2.78920M |
| Selling general administrative | 5.23M | 3.37M | 7.51M | 1.59M | 1.60M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| Reconciled depreciation | 0.22M | 0.19M | 0.30M | 0.20M | 0.06M |
| Ebit | -12.87729M | -9.64782M | -13.50698M | -4.28610M | -2.73950M |
| Ebitda | -12.68764M | -10.79619M | -13.21563M | -4.07007M | -2.67641M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -17.24251M | -12.59725M | -15.19985M | -5.26033M | -3.31084M |
| Other operating expenses | 3.53M | 2.42M | 1.63M | 1.17M | 1.13M |
| Interest expense | 0.17M | 0.00242M | 0.00211M | 0.05M | 0.06M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.07M | 0.09M | 0.11M | 0.03M | 0.00700M |
| Net interest income | -0.11707M | 0.08M | 0.09M | -0.03064M | -0.04970M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | - | - | - |
| Total revenue | - | - | - | - | - |
| Total operating expenses | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 4.28M | 1.53M | 1.59M | 0.97M | 0.57M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -13.07742M | -10.98628M | -13.51337M | -4.31674M | -2.78920M |
| Net income applicable to common shares | -13.07742M | -10.98628M | -13.51337M | -4.31674M | -2.78920M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 2.56M | 12.62M | 21.68M | 3.24M | 0.92M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.30M | 0.42M | 0.06M | 0.02M | 0.01M |
| Total liab | 5.14M | 2.56M | 1.18M | 0.93M | 1.33M |
| Total stockholder equity | -2.58880M | 10.06M | 20.50M | 2.31M | -0.40560M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.29M | 1.51M | 0.09M | 0.23M | 0.14M |
| Common stock | 44.11M | 43.97M | 43.30M | 18.47M | 11.57M |
| Capital stock | 44.11M | 43.97M | 43.30M | 18.47M | 11.57M |
| Retained earnings | -55.53532M | -42.45790M | -31.47162M | -17.95826M | -13.64152M |
| Other liab | 0.19M | 0.12M | 0.09M | 0.05M | 0.05M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | -0.00000M | - |
| Cash | 1.56M | 11.58M | 20.87M | 2.68M | 0.40M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 4.85M | 2.45M | 1.08M | 0.89M | 1.27M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | - | - | - | - | - |
| Short term debt | - | - | - | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | 8.83M | 8.55M | 8.68M | 1.80M | 1.66M |
| Property plant equipment | 0.61M | 0.44M | 0.50M | 0.50M | 0.47M |
| Total current assets | 1.95M | 12.18M | 21.18M | 2.74M | 0.45M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -2.58882M | 10.06M | 20.50M | 2.31M | -0.40576M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.09M | 0.18M | 0.25M | 0.04M | 0.04M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 0.95M | 0.48M | 0.49M | 0.16M | 0.12M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | -0.00000M | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.61M | 0.44M | 0.50M | 0.50M | 0.47M |
| Capital lease obligations | 0.25M | 0.07M | 0.13M | 0.08M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -0.03863M | -0.04034M | -0.07601M | -0.00594M | -0.08993M |
| Change to liabilities | 0.77M | 0.11M | 0.28M | 0.18M | 0.09M |
| Total cashflows from investing activities | -0.03863M | -0.04034M | -0.07601M | -0.00594M | -0.08993M |
| Net borrowings | 2.71M | -0.13917M | -0.17470M | -0.88751M | 0.74M |
| Total cash from financing activities | 2.71M | -0.24050M | 26.12M | 6.09M | 2.43M |
| Change to operating activities | -1.01017M | 1.36M | 0.07M | 0.08M | 0.05M |
| Net income | -13.07742M | -10.98628M | -13.51337M | -4.31674M | -2.78920M |
| Change in cash | -10.02036M | -9.29111M | 18.19M | 2.28M | -0.27633M |
| Begin period cash flow | 11.58M | 20.87M | 2.68M | 0.40M | 0.68M |
| End period cash flow | 1.56M | 11.58M | 20.87M | 2.68M | 0.40M |
| Total cash from operating activities | -12.68737M | -9.01026M | -7.85585M | -3.80745M | -2.61213M |
| Issuance of capital stock | 0.10M | 0.29M | 28.06M | 6.98M | 1.69M |
| Depreciation | 0.22M | 0.19M | 0.30M | 0.20M | 0.06M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 0.09M | 0.06M | -0.20412M | -0.00485M | -0.01556M |
| Sale purchase of stock | - | - | -1.71867M | - | - |
| Other cashflows from financing activities | -0.10439M | -0.38873M | -1.75887M | -1.75887M | -1.75887M |
| Change to netincome | 0.33M | 0.26M | 5.22M | 0.06M | 0.06M |
| Capital expenditures | 0.04M | 0.04M | 0.08M | 0.00594M | 0.09M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | - | - | - | - | - |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | - | - | - | - | - |
| Free cash flow | -12.72600M | -9.05061M | -7.93186M | -3.81339M | -2.70206M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| RECEF Recce Pharmaceuticals Ltd |
- -% | 0.22 | - | - | 21.51 | 102.52 | -5.8443 | |
| NVO Novo Nordisk A/S |
-0.79 1.81% | 42.96 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.6937 1.57% | 43.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.09 1.15% | 446.83 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.72 1.07% | 635.45 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Aurora Place, Sydney, NSW, Australia, 2000
| Name | Title | Year Born |
|---|---|---|
| Mr. James Hamilton-Bray Graham GAICD | CEO, MD & Exec. Director | NA |
| Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci) | Chief Scientific Director & Exec. Director | NA |
| Dr. Justin Ward | Principal Quality Chemist & Exec. Director | NA |
| Mr. Arthur Kollaras | Principal Engineer & Head of Manufacturing | NA |
| Mr. Justin Reynolds | Chief Financial Officer | NA |
| Thomas Jarrett | Operations Mang. | NA |
| Mr. Daniel Astudillo B.A., B.Com., M.B.A. | Head of Marketing | NA |
| Ms. Maggie Niewidok | Company Sec. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...